Lyons Gary A
- SEC CIK
- 0001123343
In the past year, 3 open-market sale filings worth $3.25M and no purchases.
Current role at each company
- TVTX Travere Therapeutics, Inc.Directoras of Aug 19, 2026
- NBIX Neurocrine Biosciences IncDirectoras of May 29, 2026
- RIGL Rigel Pharmaceuticals IncDirectoras of Jul 12, 2023
- ELDN Eledon Pharmaceuticals, Inc.Directoras of May 2, 2023
- FRTX Fresh Tracks Therapeutics, Inc.Directoras of May 17, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $3.25M
- 3 filings
- Net
- −$3.25M
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Lyons Gary A as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
TVTX Travere Therapeutics, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 (view filing)4:05 PM ET | Aug 17-18 | 2 days | Lyons Gary ADirector | SSale | −10.0K | $63.28 | −$632.8K | −14.0%61.5K after | 5 lots10b5-1 |
| Apr 16, 2026 (view filing) | Apr 14 | 2 days | Lyons Gary ADirector | SSale | −8.00K | $41.07 | −$328.6K | −12.2%57.5K after | 10b5-1 |
| Oct 4, 2024 (view filing) | Oct 4 | Same day | Lyons Gary ADirector | SSale | −40.0K | $14.73 | −$589.1K | −44.0%51.0K after | 2 lots10b5-1 |
NBIX Neurocrine Biosciences Inc
Director12 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | Lyons Gary ADirector | SSale | −15.0K | $152.61 | −$2.29M | −11.1%120.5K after | 10b5-1 |
| Aug 15, 2024 (view filing) | Aug 13 | 2 days | Lyons Gary ADirector | SSale | −11.6K | $150.43 | −$1.74M | −8.9%119.0K after | 10b5-1 |
| Jul 18, 2024 (view filing) | Jul 16 | 2 days | Lyons Gary ADirector | SSale | −930 | $150.03 | −$139.5K | −0.8%119.0K after | 10b5-1 |
| May 16, 2024 (view filing) | May 14 | 2 days | Lyons Gary ADirector | SSale | −12.5K | $135.63 | −$1.70M | −9.7%116.9K after | 10b5-1 |
| Dec 27, 2023 (view filing) | Dec 22 | 5 days | Lyons Gary ADirector | SSale | −10.0K | $130.04 | −$1.30M | −4.9%193.7K after | 10b5-1 |
| Dec 5, 2023 (view filing) | Dec 1 | 4 days | Lyons Gary ADirector | SSale | −5.00K | $116.77 | −$583.9K | −2.4%203.7K after | 10b5-1 |
| Sep 14, 2023 (view filing) | Sep 12 | 2 days | Lyons Gary ADirector | SSale | −5.00K | $115.02 | −$575.1K | −2.4%203.7K after | 10b5-1 |
| Sep 6, 2023 (view filing) | Sep 1 | 5 days | Lyons Gary ADirector | SSale | −5.00K | $110.06 | −$550.3K | −2.4%203.7K after | 10b5-1 |
| Nov 2, 2022 (view filing) | Oct 31 | 2 days | Lyons Gary ADirector | SSale | −15.0K | $114.76 | −$1.72M | −6.9%203.7K after | |
| Oct 5, 2022 (view filing) | Oct 4 | 1 day | Lyons Gary ADirector | SSale | −5.00K | $110.54 | −$552.7K | −2.4%203.7K after |